Metraipolis › archive › dc_8ea6b34aa4b4

Real-world safety of Tepotinib: Insights from the Food and Drug Administration Adverse Event Reporting System — Europe PMC PMID:41411333

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41411333
DOI
10.1371/journal.pone.0339005
License (as archived)
solo-consultazione
Archived
2026-10-08T15:15:41.030Z
SHA-256 of the archived text
a548e395228daccd2b91e82a82c24715e46b573a3f1aa0439f6433bb2d1117b4
Stable URL of this page
https://metraipolis.com/documento/dc_8ea6b34aa4b4

How to cite

Real-world safety of Tepotinib: Insights from the Food and Drug Administration Adverse Event Reporting System — Europe PMC PMID:41411333 — Europe PMC (en), https://europepmc.org/article/MED/41411333 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8ea6b34aa4b4 (Metraipolis archive dc_8ea6b34aa4b4, sha256 a548e395228daccd2b91e82a82c24715e46b573a3f1aa0439f6433bb2d1117b4)
BibTeX
@misc{dc8ea6b34aa4b4,
  title = {Real-world safety of Tepotinib: Insights from the Food and Drug Administration Adverse Event Reporting System — Europe PMC PMID:41411333},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41411333},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8ea6b34aa4b4; sha256 a548e395228daccd2b91e82a82c24715e46b573a3f1aa0439f6433bb2d1117b4},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41411333. Agents can read the archived copy with the MCP tool read_document.